A Blood test to measure proteins for a multi-cancer diagnostic

Current cancer screening is primarily restricted to various forms of imaging. For breast and lung cancer screening there are a significant percentage of false positive tests. Testing for colorectal involves invasive colonoscopies. For some of these tests, recent recommendations to extend the screening age from 45 to 40 put more pressure on a screening system that already has difficulty meeting the suggested recommendations for screening – especially in underserved rural areas. There is a need for a simple effective screening method that can test the recommended population. Samples (154 cancer and 119 normals) were tested for five different cancers (breast, lung, colorectal, ovarian, and pancreatic). The test included measurement of extracellular protein kinase activity, other kinase activities, and antibodies to altered cancer proteins (both IgG and IgM forms). The resulting test had a sensitivity of 100% with an overall specificity of 97%. Importantly, the test also identified the cancer tissue of origin (TOO) 98% of the time minimizing the need for downstream confirmatory testing and biopsies. The test had the added benefit of differentiating cancer subtypes for lung and ovarian cancers. The groundwork was established for an effective multi-cancer early detection (MCED) test for five different cancers